Cholangiocarcinoma (CCA)
Patient Condition
Advanced intrahepatic cholangiocarcinoma recurred after surgery, positive for FGFR2 fusion gene (confirmed by FoundationOne CDx test), multiple liver metastases and retroperitoneal lymph node metastases, CA19 -9 680U/mL.
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| Diagnosis of postoperative recurrence | ||
| FGFR-targeted therapy | ||
| efficacy assessments | ||
| ongoing treatment for |
Treatment Outcome
| before | Advanced intrahepatic cholangiocarcinoma recurred after surgery, FGFR2 fusion positive, multiple liver metastases, CA19-9 680U/mL |
|---|---|
| after | After 14 cycles of Pemigatinib treatment, liver metastases shrank by 60%, CA19 -9 dropped to 120U/mL, reaching PR, and PFS exceeded 13 months |
| highlight | Targeted treatment with Pemigatinib for FGFR2 fusion positive cholangiocarcinoma reduced liver metastases by 60%, and PFS exceeded 13 months |